Pluristyx | panCELLA

A fully integrated Pluristyx and panCELLa offer an enlarged portfolio and aims to become the leading provider of iPSC and cell therapy services and solutions. The combined product and service offerings provide clients with the fastest speed to clinic and the best route to commercialization.    

Pluristyx today offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while PanCella offers an array of unique and effective technologies with particular strength in gene editing. The long-term focus of the combined company is to offer an expanding technology base and products and deepen operating capabilities to become the global leader in clinical-grade, genetically modified iPSCs with the lowest barrier to entry for cell therapy development.